Share on

Global Peptic Ulcer Drugs Market Size, Share, Trends, COVID-19 impact & Growth Analysis Report – Segmented By drugs type, ulcer, and region – Industry Forecast (2022 to 2027)

Published: January, 2022
ID: 12181
Pages: 200
Formats: report pdf report excel report power bi report ppt

Global Peptic Ulcer Drugs Market Size (2022 to 2027)

The global peptic ulcer drugs market was valued at around USD 4.80 billion in 2022 and is expected to grow at a compound annual growth rate of 2.64% from 2022 to 2027 and worth USD 5.47 billion by 2027.

A peptic ulcer is a breakage in the inner surface of the stomach or the upper part of the intestine in the gastrointestinal tract. Ulcers form when the protective wall of the intestine or stomach is broken. When the lining is interrupted the acidic gastric juices that contain hydrochloric acid and an enzyme called pepsin irritates the stomach and cause inflammation around it leading to ulcers.

Peptic ulcers represent a group of ulcerative disorders such as gastritis, gastric ulcers, and duodenal ulcers, or gastroesophageal reflux disease (GERD). Treatment of peptic ulcers is carried out with drugs such as proton pump inhibitors (PPIs), competitive potassium acid inhibitors, antacids, H2 antagonists, antibiotics, and ulcer protective drugs such as sucralfate.


The peptic ulcer drugs market is expected to grow at a rapid rate during the forecast period. Lifestyle factors such as increased consumption of soft drinks, alcoholism, fatty foods, and stress can cause peptic ulcers, which is expected to accelerate the growth of the global peptic ulcer drugs market. Peptic ulcers can cause disturbance in lifestyle for older people due to loss of appetite, chronic fatigue, and lethargy. Hence, the increase in this population is a key factor that is expected to drive the market during the forecast period.

Additionally, the increase in chronic diseases and increase in consumption of drugs such as aspirin, ibuprofen, and other inflammatory drugs are the other factors that are predicted to increase the peptic ulcers drugs market. According to the American Cancer Society, In U.S, 32,500 people had stomach cancer in 2018, these numbers rose to 35,500 cases in 2020, while nearly 11,500 people are estimated to die due to complications. According to a 2021 recent study conducted at Harvard University, more than 8 million people suffer from peptic ulcers each year. The increasing number of cases of people suffering from gastrointestinal ulcers is driving the demand for peptic ulcer drugs across the world. In addition, the growing healthcare awareness and availability of peptic ulcer drugs are expected to contribute to the market growth in the coming years.

Growing demand for the use of non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin, paracetamol, and others and growing awareness about peptic ulcers and their treatment options are factors expected to trigger the growth of the peptic ulcer drugs market.


However, the side effects of long-term use of PPIs, changes in government policies, the loss of market exclusivity for most peptic ulcer drugs, and the limited R&D efforts in the field of peptic ulcer drugs are factors that will hamper the growth of peptic ulcer drugs market across the world.


A major development for the peptic ulcer drugs market is the increasing preference of patients to opt for drugs to cure their peptic ulcer rather than undergoing surgery. In addition, the increasing attention to research and development activities to find new therapies, sponsored primarily by changing healthcare policies and governments, is also playing an important role in the growth of the peptic ulcer drugs market.


The reimbursement of medical costs related to certain tests and medicines in some countries, especially in APAC regions, is challenging the growth of the peptic ulcer drugs market.

COVID-19 Impact on the global peptic ulcer drugs market:

The COVID-19 pandemic has crippled a number of industrial processes, causing unprecedented economic losses. In the coming quarters of 2020 and 2021, these combined difficulties in transmitting and treating infections are expected to delay the diagnosis and cure of gastrointestinal illnesses. Decreasing doctor and hospital visits due to the prioritization of COVID-19 care for non-essential health conditions would limit market development. Due to the availability of COVID-19 vaccines, the peptic ulcer drug market is expected to rebound towards pre-pandemic market demands. Pharmaceutical companies are thriving in these difficult times due to the increasing demand for drugs around the world. Likewise, the demand for these ulcer drugs is growing tremendously as large pharmaceutical companies focus more on R&D activities to develop new drugs and meet the demand for over-the-counter drugs in various stores. Hence, the market is expected to show positive growth during the forecast period.

The market is resuming with improved and emerging economies across the world. In addition, local governments are organizing health services to deal with complications from COVID-19.




Market Size Available

2021 to 2027

Base Year


Forecast Period

2022 to 2027

Segments Covered

By drugs type, ulcer, and region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa


This research report on the global peptic ulcer drugs market has been segmented and sub-segmented based on drugs type, ulcer, and region.

Global Peptic Ulcer Drugs Market - By Drug Type:

  • Proton Pump Inhibitors (PPIs)
  • Anti-Histamines
  • H2 Antagonists
  • Antacids
  • Antibiotics
  • Others

Global Peptic Ulcer Drugs Market -By Ulcer Type:

  • Gastric Ulcers
  • Duodenal Ulcer
  • Esophageal Ulcer

Global Peptic Ulcer Drugs Market -By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Geographically, North America and Europe collectively accounted for 67% of the total revenue share in the global peptic ulcer drugs market in 2020. The U.S. peptic ulcer drug market was estimated at USD 1.4 billion in 2020, while Canada is estimated to grow at a CAGR of 2.55% during the forecast period. North America was worth USD 2.06 billion in 2020 and is expected to hold the largest market share in the coming years. This market growth in the region is due to the increase in incidences of peptic ulcers patients in the United States.

The Asia-Pacific regional market held 23% of the overall peptic ulcer drug market share and this trend is estimated to gain similar growth during the forecast period, owing to the increased case of recurrent peptic ulcers in patients. China will be one of the fastest-growing Asian countries in the APAC regions. Led by countries like Australia, India, and South Korea, the Asia-Pacific market is expected to reach USD 698 million by 2026.

The MEA market is expected to grow at a slow and steady rate during the forecast period, owing to the low accessibility of peptic ulcer drugs and poor healthcare infrastructure in the region. Other regional markets such as Saudi Arabia and UAE, will be growing at a CAGR of 2.8% and 2.1% respectively over the period 2020-2027.

In Europe, Germany is expected to grow at 2.8% CAGR from 2021 to 2026. The growing awareness of peptic ulcers in humans is one of the emerging trends in the European peptic ulcer drugs market in the coming years. The growth of the European market can be attributed to the increasing number of patients suffering from peptic ulcers as well as increasing healthcare spending in European countries such as Germany, the UK, and France. The market demand in Germany is mainly due to the easy availability of medicines and effective treatment options for peptic ulcers.

On the other hand, Latin America is expected to occupy a moderate share in the global market during the forecast period in the global market. This is attributable to factors such as lesser healthcare spending in countries like Peru, Chile, and Ecuador from 2021 to 2026.


Novartis AG, Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca, Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceuticals Company Limited, Pfizer Inc., Helicure AB and Eumedica Pharmaceuticals are some of the companies currently dominating the global peptic ulcer drugs market and profiled in this report.


  • In October 2019, Novitium Pharma LLC recalled ranitidine hydrochloride capsules in the United States due to elevated levels of NDMA (N-nitrosodimethylamine), a suspected human carcinogen, above FDA limits.
  • In Novermber 2019, to expand their product line, major market players are focusing on product acceptance and launch. Talicia, treatment for Helicobacter pylori infection in adults.
  • The company ‘RedHill Biopharma’ announced the commercial launch in the United States of Talicia, a capsule to treat H. pylori infection in patients in March 2020. The announcement made the company one of the leading pharmaceutical companies in the world.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample